Experienced in Cholangiocarcinoma (Bile Duct Cancer)

Jianhua Yu

Shaoxing, CN 
Experienced in Cholangiocarcinoma (Bile Duct Cancer)
Shaoxing, CN 
OverviewLocationsClinical Research

Overview

Jianhua Yu practices in Shaoxing, China. Yu is rated as an Experienced expert by MediFind in the treatment of Cholangiocarcinoma (Bile Duct Cancer). Their top areas of expertise are Gallbladder Cancer, Gallbladder Disease, Congenital Bronchobiliary Fistula, Neurosyphilis, and Pancreaticoduodenectomy.

Their clinical research consists of co-authoring 61 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, they have co-authored 8 articles in the study of Cholangiocarcinoma (Bile Duct Cancer).

Locations

Shaoxing, 312000, China
Other Locations
Xuzhou, 221008, China
Hangzhou, China
Lishui, China
Longquan, 323700, China
Longxi, China
Xixi, China
P.R. China, Xiamen, 361000, China
Hangzhou, 310023, China

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

Switching From Tenofovir Disoproxil Fumarate-based Antiretroviral Therapy Regimens to Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virally Suppressed Adults With HIV-1 Infection
Switching From Tenofovir Disoproxil Fumarate-based Antiretroviral Therapy Regimens to Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virally Suppressed Adults With HIV-1 Infection
Enrollment Status: Active_not_recruiting
Publish Date: December 21, 2023
Intervention Type: Drug
Study Drugs: Bictegravir, Emtricitabine, Tenofovir alafenamide, Tenofovir disoproxil fumarate-based antiretroviral regimen
Study Phase: Phase 4
Impact of Triptolide Wilfordii on Viral Suppression, Immune Recovery and Immune Activation Biomarkers in Treatment-naive HIV-1 Infection: a Randomized, Double-blinded, Placebo-controlled Study
Impact of Triptolide Wilfordii on Viral Suppression, Immune Recovery and Immune Activation Biomarkers in Treatment-naive HIV-1 Infection: a Randomized, Double-blinded, Placebo-controlled Study
Enrollment Status: Completed
Publish Date: April 08, 2022
Intervention Type: Drug
Study Drug: Triptolide Wilfordii
Study Phase: Phase 3
View 1 Less Clinical Trial

61 Total Publications

Comparative analysis of deep learning and radiomics models in predicting hepatocellular carcinoma differentiation via ultrasound.
Comparative analysis of deep learning and radiomics models in predicting hepatocellular carcinoma differentiation via ultrasound.
Journal: Frontiers in medicine
Published: August 14, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Yu's expertise for a condition
ConditionClose
      View All 17 Experienced Conditions
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile